1. AMVUTTRA
Amvuttra is a brand drug owned by Alnylam Pharmaceuticals Inc. It is Used for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It was approved for market use on Jun 13, 2022. Amvuttra uses Vutrisiran Sodium as an active ingredient.
Total Patents:
13
Expired Patents:
0
Amvuttra's NCE-1 date is Jun 13, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Amvuttra
2. AQVESME
Aqvesme is a brand drug owned by Agios Pharmaceuticals Inc. It was approved for market use on Dec 23, 2025. Aqvesme uses Mitapivat Sulfate as an active ingredient.
Total Patents:
6
Expired Patents:
0
Aqvesme's NCE-1 date is Feb 17, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Aqvesme
3. BIXLENVO
Bixlenvo is a brand drug owned by Gilead Sciences Inc. It was approved for market use on Aug 27, 2026. Bixlenvo uses Bictegravir Sodium; Lenacapavir Sodium as an active ingredient.
Total Patents:
8
Expired Patents:
0
Bixlenvo's NCE-1 date is Dec 22, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Bixlenvo
4. BIXLENVO SUNLENCA STARTER PACK (COPACKAGED)
Bixlenvo Sunlenca Starter Pack (copackaged) is a brand drug owned by Gilead Sciences Inc. It was approved for market use on Aug 27, 2026. Bixlenvo Sunlenca Starter Pack (copackaged) uses Bictegravir Sodium, Lenacapavir Sodium; Lenacapavir Sodium as an active ingredient.
Total Patents:
8
Expired Patents:
0
Bixlenvo Sunlenca Starter Pack (copackaged)'s NCE-1 date is Dec 22, 2026 which is when its patents will be open to challenges.
5. BLUDIGO
Bludigo is a brand drug owned by Provepharm Sas. It was approved for market use on Jul 8, 2022. Bludigo uses Indigotindisulfonate Sodium as an active ingredient.
Total Patents:
3
Expired Patents:
0
Bludigo's NCE-1 date is Jul 08, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Bludigo
6. CAMZYOS
Camzyos is a brand drug owned by Bristol Myers Squibb Co. It is Used for improving functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in NYHA class II-III. It was approved for market use on Apr 28, 2022. Camzyos uses Mavacamten as an active ingredient.
Total Patents:
3
Expired Patents:
0
Camzyos's NCE-1 date is Apr 28, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Camzyos
7. CIBINQO
Cibinqo is a brand drug owned by Pfizer Inc. It is Used for treating adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products. It was approved for market use on Jan 14, 2022. Cibinqo uses Abrocitinib as an active ingredient.
Total Patents:
3
Expired Patents:
0
Cibinqo's NCE-1 date is Jan 14, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Cibinqo
8. ELUCIREM
Elucirem is a brand drug owned by Guerbet. It was approved for market use on Sep 21, 2022. Elucirem uses Gadopiclenol as an active ingredient.
Total Patents:
4
Expired Patents:
0
Elucirem's NCE-1 date is Sep 21, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Elucirem
9. KRAZATI
Krazati is a brand drug owned by Bristol Myers Squibb Co. It is Used for treating locally advanced or metastatic non-small cell lung cancer in adult patients with a specific KRAS mutation who have already undergone prior systemic therapy. It was approved for market use on Dec 12, 2022. Krazati uses Adagrasib as an active ingredient.
Total Patents:
5
Expired Patents:
0
Krazati's NCE-1 date is Dec 12, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Krazati